AI Article Synopsis
- - The study surveyed clinicians involved in treating subarachnoid hemorrhage (SAH) to assess how often and why human albumin (ALB) is used, given that it's not commonly included in institutional protocols.
- - Results from 362 responses showed that while most institutions don’t have ALB in their SAH treatment protocols, nearly half of the respondents use it anyway, particularly in the US and in facilities with dedicated neuro-ICUs.
- - A significant majority (75%) of clinicians believe there is a need for a clinical trial to evaluate the safety and effectiveness of ALB in SAH patients.
Article Abstract
Background: Subarachnoid hemorrhage (SAH) is a devastating disease. Nimodipine is the only medical treatment shown to improve outcome of SAH patients. Human albumin (ALB) may exert neuroprotection in SAH. However, current usage of ALB in SAH is not known. We conducted an international survey of clinicians involved in the care of SAH patients to determine current practice of ALB administration in SAH.
Methods: We constructed a 27-question survey. Our sampling frame consisted of neurointensivists, general intensivists, neurocritical care nurses, critical care pharmacists, and neurosurgeons. The survey was available from 11/15/2012 to 12/15/2012. We performed mostly descriptive statistical analysis.
Results: We obtained 362 responses from a diverse range of world regions. Most respondents were intensivist physicians (88 %), who worked in academic institutions (73.5 %) with a bed capacity >500 (64.1 %) and an established institutional management protocol for SAH patients (70.2 %). Most respondents (83.5 %) indicated that their institutions do not incorporate ALB in their protocol, but half of them (45.9 %) indicated using ALB outside it. ALB administration is influenced by several factors: geographic variation (more common among US respondents); institutions with a dedicated neuroICU; and availability of SAH management protocol. Most respondents (75 %) indicated that a clinical trial to test the efficacy of ALB in SAH is needed.
Conclusions: In this survey we found that ALB administration in SAH patients is common and influenced by several factors. Majority of respondents support a randomized clinical trial to determine the safety and efficacy of ALB administration in SAH patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12028-013-9942-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Non-Traumatic Intracranial Hemorrhage and Risk of Incident Dementia in U.S. Medicare Beneficiaries.
Stroke
January 2025
Neurology, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, UNITED STATES.
To study the risk of incident dementia after a non-traumatic intracranial hemorrhage in a diverse US population, and evaluate if this risk is different for the subtypes of intracranial hemorrhage. We performed a retrospective cohort study using both inpatient and outpatient claims data on Medicare beneficiaries between January 1, 2008 and December 31, 2018. The exposure was a new diagnosis of non-traumatic intracranial hemorrhage, defined as a composite of intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), and subdural hemorrhage (SDH).
View Article and Find Full Text PDFRisk of stroke associated with proton pump inhibitor use among individuals with and without pre-existing cardiovascular diseases: a systematic review and meta-analysis.
J Cardiothorac Surg
January 2025
Department of Paediatrics, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth, Maharashtra, Pune, 411018, India.
Background: Proton pump inhibitors (PPIs) are commonly used for managing gastroesophageal disorders but concerns about their potential association with increased stroke risk have emerged, especially among patients with pre-existing cardiovascular conditions such as acute coronary syndrome (ACS). This systematic review and meta-analysis aim to assess the risk of stroke associated with PPI use, stratified by the presence or absence of pre-existing CVD.
Methods: This review was conducted following the PRISMA guidelines and included studies up to March 2024 from PubMed, Embase, and Web of Science.
Factors associated with the presence of Candida spp. in the oral and tracheobronchial secretions of patients admitted to an adult intensive care unit.
Diagn Microbiol Infect Dis
January 2025
Professor at the Department of Physiotherapy, the Postgraduate Program in Health Sciences and the Postgraduate Program in Rehabilitation and Functional Performance Universidade Federal dos Vales do Jequitinhonha e Mucuri, Brazil. Electronic address:
to verify factors associated with the presence of Candida spp. in oral and tracheobronchial secretions of 135 patients admitted to an adult ICU, general of the Santa Casa de Caridade, of Diamantina, Minas Gerais, Brazil. Oral samples showed significant differences between colonized and non-colonized patients in the variables age (p < 0.
View Article and Find Full Text PDFLyme disease associated neurological and musculoskeletal symptoms: A systematic review and meta-analysis.
Brain Behav Immun Health
February 2025
University Center for Research and Development, Chandigarh University, Mohali, Punjab, India.
Background And Objective: Lyme disease, caused by , presents major health challenges worldwide, leading to serious neurological and musculoskeletal issues that impact patients' lives and healthcare systems. This systematic review and meta-analysis aim to determine the prevalence and link between Lyme disease and these complications, aiming to enhance clinical and public health approaches.
Methods: We systematically searched PubMed, EMBASE, and Web of Science up until April 01, 2024, to find studies reporting the prevalence and severity of neurological and musculoskeletal complications associated with Lyme disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!